[N:1]1[CH:6]=[CH:5][N:4]=[C:3]2[C:7](=[O:11])[O:8][C:9](=[O:10])[C:2]=12.[C:12]1([C:18]2[N:19]=[C:20]3[N:25]=[C:24]([NH2:26])[CH:23]=[CH:22][N:21]3[CH:27]=2)[CH:17]=[CH:16][CH:15]=[CH:14][CH:13]=1>CN(C1C=CN=CC=1)C.CN(C=O)C>[C:12]1([C:18]2[N:19]=[C:20]3[N:25]=[C:24]([NH:26][C:7]([C:3]4[C:2]([C:9]([OH:8])=[O:10])=[N:1][CH:6]=[CH:5][N:4]=4)=[O:11])[CH:23]=[CH:22][N:21]3[CH:27]=2)[CH:13]=[CH:14][CH:15]=[CH:16][CH:17]=1Furo[3,4-b]pyrazine-5,7-dione (736 mg, 4.9 mmol) and DMAP (58 mg, cat.) were added to a solution of 2-phenyl-imidazo[1,2-a]pyrimidin-7-ylamine (example 1, step 1, 1.00 g, 4.8 mmol) in DMF (25 ml). The mixture was heated to 78° C. overnight, and cooled to RT. The formed precipitate was collected by filtration, and residual solvent was removed under vacuum. The thus obtained crude product (800 mg, 47%) was used in the next step without further purification.